Keyphrases
Baseline Characteristics
100%
Patient Characteristics
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Patients with Heart Failure
100%
Left Ventricular Ejection Fraction
28%
Angiotensin Receptor Blockers
28%
Asia-Pacific
14%
Sex Distribution
14%
Heart Failure Hospitalization
14%
Age Distribution
14%
Central Europe
14%
New York Heart Association Class
14%
Structural Heart Disease
14%
Diuretics
14%
Chronic Kidney Disease
14%
Contemporary Group
14%
High Prevalence
14%
Unique Identifier
14%
Regional Variation
14%
Latin America (LATAM)
14%
North America
14%
Beta-blockers
14%
Plasma Concentration
14%
Global Outcome
14%
Inclusion Criteria
14%
Clinical Trial Registry
14%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
14%
Valsartan
14%
Baseline Therapy
14%
Angiotensin-converting Enzyme Inhibitor (ACEi)
14%
Calcium Channel Blockers
14%
Comorbidity
14%
Western Europe
14%
Type 1 Diabetes Mellitus (T1DM)
14%
Mineralocorticoid Receptor Antagonists
14%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Preserved Ejection Fraction
100%
Congestive Heart Failure
100%
Angiotensin Receptor Antagonist
28%
Heart Disease
14%
Chronic Kidney Failure
14%
Mineralocorticoid Antagonist
14%
Calcium Channel Blocker
14%
Diuretics
14%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Valsartan
14%
Enkephalinase Inhibitor
14%
Clinical Trial
14%
Valsartan/Sacubitril
14%
Comorbidity
14%
Prevalence
14%
Angiotensin Receptor
14%
Diabetes Mellitus
14%
Brain Natriuretic Peptide
14%